The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy

Aims: The trials upon which recommendations for the use of cardiac resynchronization therapy (CRT) in heart failure used optimal medical therapy (OMT) before sodium‐glucose co‐transporter 2 inhibitors (SGLT2i). Moreover, the SGLT2i heart failure trials included only a small proportion of participant...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Bray, JJ, Coronelli, M, Scott, SG, Henry, JA, Couch, LS, Ahmad, M, Ormerod, J, Gamble, J, Betts, TR, Lewis, A, Rider, OJ, Green, PG, Herring, N
Formato:	Journal article
Idioma:	English
Publicado em:	Wiley Open Access 2024

Registros relacionados

Endocardial left ventricular pacing for cardiac resynchronization: systematic review and meta-analysis.
por: Gamble, J, et al.
Publicado em: (2017)

Endocardial left ventricular pacing across the interventricular septum for cardiac resynchronization therapy: clinical results of a pilot study
por: Gamble, JHP, et al.
Publicado em: (2018)

Procedural success of left ventricular lead placement for cardiac resynchronization therapy: A meta-analysis
por: Gamble, J, et al.
Publicado em: (2015)

An active fixation quadripolar left ventricular lead for cardiac resynchronization therapy with reduced postoperative complication rates
por: Robertson, C, et al.
Publicado em: (2022)

Pneumopericardium and pneumomediastinum after implantation of a cardiac resynchronization pacemaker
por: Green, P, et al.
Publicado em: (2019)

Cost-effectiveness analysis of quadripolar versus bipolar left ventricular leads for cardiac resynchronization defibrillator therapy in a large, multicenter UK registry.
por: Behar, J, et al.
Publicado em: (2016)

New mechanisms and concepts for cardiac-resynchronization therapy.
por: Neubauer, S, et al.
Publicado em: (2014)

Devices for cardiac resynchronization : technologic and clinical aspects /
por: Barold, S. Serge, et al.
Publicado em: (2008)

Clinical cardiac pacing, defibrillation, and resynchronization therapy /
por: Ellenbogen, Kenneth A.
Publicado em: (2007)

Cardiac resynchronization therapy in inotrope‐dependent heart failure: a meta‐analysis
por: Al‐Shakarchi, NJ, et al.
Publicado em: (2024)

Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry
por: Behar, JM, et al.
Publicado em: (2015)

Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction
por: Henry, JA, et al.
Publicado em: (2024)

Can machine learning improve patient selection for cardiac resynchronization therapy?
por: Santus, Enrico, et al.
Publicado em: (2020)

Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: Long-term follow-up from a multicenter registry
por: Behar, J, et al.
Publicado em: (2015)

Artificial intelligence models in prediction of response to cardiac resynchronization therapy: a systematic review
por: Nazar, W, et al.
Publicado em: (2023)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
por: Herrington, WG, et al.
Publicado em: (2021)

Cine dyscontractility index: a novel marker of mechanical dyssynchrony that predicts response to cardiac resynchronization therapy
por: Werys, K, et al.
Publicado em: (2016)

Role of cardiac energetics in aortic stenosis disease progression: identifying the high-risk metabolic phenotype
por: Monga, S, et al.
Publicado em: (2023)

Improved papillary muscle function attenuates functional mitral regurgitation in patients with dilated cardiomyopathy after cardiac resynchronization therapy.
por: Karvounis, H, et al.
Publicado em: (2006)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management
por: Katsiki, N, et al.
Publicado em: (2017)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
por: Fletcher, RA, et al.
Publicado em: (2024)

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
por: Vasilakou, D, et al.
Publicado em: (2013)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
por: Hinton, W, et al.
Publicado em: (2020)

Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
por: Rådholm, K, et al.
Publicado em: (2019)

Serial cardiac magnetic resonance of an evolving subacute pericardial hematoma
por: Watson, WD, et al.
Publicado em: (2019)

Myocardial energy response to glyceryl trinitrate: physiology revisited
por: Watson, WD, et al.
Publicado em: (2020)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
por: McGovern, A, et al.
Publicado em: (2017)

Investigating the disease is the key to the obesity stigma
por: Rayner, JJ, et al.
Publicado em: (2021)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
por: McGovern, A, et al.
Publicado em: (2017)

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis
por: Patel, SM, et al.
Publicado em: (2024)

Non-invasive investigation of myocardial energetics in cardiac disease using 31P magnetic resonance spectroscopy
por: Peterzan, MA, et al.
Publicado em: (2020)

GLUCOSE ANALOG INHIBITORS OF GLYCOGEN-PHOSPHORYLASE
por: Johnson, L, et al.
Publicado em: (1994)

Pushing and pulling the cardiac sodium/hydrogen exchanger.
por: Vaughan-Jones, R, et al.
Publicado em: (2008)

Maternal cardiac changes in women with obesity and gestational diabetes mellitus
por: Thirunavukarasu, S, et al.
Publicado em: (2022)

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
por: Vale, C, et al.
Publicado em: (2024)

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
por: Shah, S, et al.
Publicado em: (2018)

Response by Peterzan et al to letter regarding article, “Cardiac energetics in patients with aortic stenosis and preserved versus reduced ejection fraction”
por: Peterzan, MA, et al.
Publicado em: (2020)

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
por: Chung, YJ, et al.
Publicado em: (2021)

Effects of resynchronization with progesterone and prostaglandin F2• on estrus response and pregnancy rate in beef cattle
por: A. Malik,, et al.
Publicado em: (2011)

Reproductive efficiency through estrus resynchronization, timed artificial insemination and spermatozoa separation in beef cattle
por: Abd Malik, .
Publicado em: (2012)